Discovery of an Unexpected Similarity in Ligand Binding between BRD4 and PPARγ

被引:2
作者
Humbeck, Lina [1 ,2 ]
Pretzel, Jette [1 ]
Spitzer, Saskia [1 ]
Koch, Oliver [1 ,3 ]
机构
[1] TU Dortmund Univ, Fac Chem & Chem Biol, D-44227 Dortmund, Germany
[2] Boehringer Ingelheim Pharma GmbH & Co KG, Computat Chem, Med Chem, Birkendorferstr 65, D-88397 Biberach, Germany
[3] Westfalische Wilhelms Univ Munster, Inst Pharmaceut & Med Chem, D-48149 Munster, Germany
关键词
DRUG DISCOVERY; PROTEIN; INHIBITORS; DESIGN; POTENT; VISUALIZATION; PHARMACOLOGY; EXPLORATION; UNIVERSE; TARGET;
D O I
10.1021/acschembio.1c00323
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Knowledge about interrelationships between different proteins is crucial in fundamental research for the elucidation of protein networks and pathways. Furthermore, it is especially critical in chemical biology to identify further key regulators of a disease and to take advantage of polypharmacology effects. Here, we present a new concept that combines a scaffold-based analysis of bioactivity data with a subsequent screening to identify novel inhibitors for a protein target of interest. The initial scaffold-based analysis revealed a flavone-like scaffold that can be found in ligands of different unrelated proteins indicating a similarity in ligand binding. This similarity was further investigated by testing compounds on bromodomain-containing protein 4 (BRD4) that were similar to known ligands of the other identified protein targets. Several new BRD4 inhibitors were identified and proven to be validated hits based on orthogonal assays and X-ray crystallography. The most important discovery was an unexpected relationship between BRD4 and peroxisome-proliferator activated receptor gamma (PPAR gamma). Both proteins share binding site similarities near a common hydrophobic subpocket which should allow the design of a polypharmacology-based ligand targeting both proteins. Such dual-BRD4-PPAR gamma modulators open up new therapeutic opportunities, because both are important drug targets for cancer therapy and many more important diseases. Thereon, a complex structure of sulfasalazine was obtained that involves two bromodomains and could be a potential starting point for the design of a bivalent BRD4 inhibitor.
引用
收藏
页码:1255 / 1265
页数:11
相关论文
共 50 条
  • [21] Discovery of a new chemical series of BRD4(1) inhibitors using protein-ligand docking and structure-guided design
    Duffy, Bryan C.
    Liu, Shuang
    Martin, Gregory S.
    Wang, Ruifang
    Hsia, Ming Min
    Zhao, He
    Guo, Cheng
    Ellis, Michael
    Quinn, John F.
    Kharenko, Olesya A.
    Norek, Karen
    Gesner, Emily M.
    Young, Peter R.
    McLure, Kevin G.
    Wagner, Gregory S.
    Lakshminarasimhan, Damodharan
    White, Andre
    Suto, Robert K.
    Hansen, Henrik C.
    Kitchen, Douglas B.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2015, 25 (14) : 2818 - 2823
  • [22] Discovery of a new class of PROTAC BRD4 degraders based on a dihydroquinazolinone derivative and lenalidomide/pomalidomide
    Zhang, Fangqing
    Wu, Zhenwei
    Chen, Pan
    Zhang, Jian
    Wang, Tao
    Zhou, Jinpei
    Zhang, Huibin
    BIOORGANIC & MEDICINAL CHEMISTRY, 2020, 28 (01)
  • [23] Discovery of BRD4 bromodomain inhibitors by fragment-based high-throughput docking
    Zhao, Hongtao
    Gartenmann, Lisa
    Dong, Jing
    Spiliotopoulos, Dimitrios
    Caflisch, Amedeo
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2014, 24 (11) : 2493 - 2496
  • [24] Discovery of novel trimethoxy-ring BRD4 bromodomain inhibitors: AlphaScreen assay, crystallography and cell-based assay
    Chen, Zhifeng
    Zhang, Hao
    Liu, Shien
    Xie, Yiqian
    Jiang, Hao
    Lu, Wenchao
    Xu, Heng
    Yue, Liyan
    Zhang, Yuanyuan
    Ding, Hong
    Zheng, Mingyue
    Yu, Kunqian
    Chen, Kaixian
    Jiang, Hualiang
    Luo, Cheng
    MEDCHEMCOMM, 2017, 8 (06) : 1322 - 1331
  • [25] Theoretically exploring selective-binding mechanisms of BRD4 through integrative computational approaches
    Luo, D.
    Tong, J. B.
    Xiao, X. C.
    Bian, S.
    Zhang, X.
    Wang, J.
    Xu, H. Y.
    SAR AND QSAR IN ENVIRONMENTAL RESEARCH, 2021, 32 (12) : 985 - 1011
  • [26] Different orientations of low-molecular-weight fragments in the binding pocket of a BRD4 bromodomain
    Lolli, Graziano
    Battistutta, Roberto
    ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY, 2013, 69 : 2161 - 2164
  • [27] Discovery of novel coumarin derivatives as potent and orally bioavailable BRD4 inhibitors based on scaffold hopping
    Zhang, Zhimin
    Gu, Lili
    Wang, Beibei
    Huang, Wenhai
    Zhang, Yanmin
    Ma, Zhen
    Zeng, Shenxin
    Shen, Zhengrong
    JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2019, 34 (01) : 808 - 817
  • [28] Discovery, X-ray Crystallography, and Anti-inflammatory Activity of Bromodomain-containing Protein 4 (BRD4) BD1 Inhibitors Targeting a Distinct New Binding Site
    Liu, Zhiqing
    Li, Yi
    Chen, Haiying
    Lai, Hsien-Tsung
    Wang, Pingyuan
    Wu, Shwu-Yuan
    Wold, Eric A.
    Leonard, Paul G.
    Joseph, Sarah
    Hu, Haitao
    Chiang, Cheng-Ming
    Brasier, Allan R.
    Tian, Bing
    Zhou, Jia
    JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (03) : 2388 - 2408
  • [29] Discovery of [1,2,4]triazolo[1,5-a]pyrimidine derivatives as new bromodomain-containing protein 4 (BRD4) inhibitors
    Wang, Shuai
    Shen, Dandan
    Zhao, Lijie
    Yuan, Xiaohan
    Cheng, Jialing
    Yu, Bin
    Zheng, Yichao
    Liu, Hongmin
    CHINESE CHEMICAL LETTERS, 2020, 31 (02) : 418 - 422
  • [30] Straightforward hit identification approach in fragment-based discovery of bromodomain-containing protein 4 (BRD4) inhibitors
    Borysko, Petro
    Moroz, Yurii S.
    Vasylchenko, Oleksandr V.
    Hurmach, Vasyl V.
    Starodubtseva, Anastasia
    Stefanishena, Natalia
    Nesteruk, Kateryna
    Zozulya, Sergey
    Kondratov, Ivan S.
    Grygorenko, Oleksandr O.
    BIOORGANIC & MEDICINAL CHEMISTRY, 2018, 26 (12) : 3399 - 3405